miR‑218 functions as a tumor suppressor gene in cervical cancer

Liu,Zhen; Mao,Lin; Wang,Linlin; Zhang,Hong; Hu,Xiaoxia

doi:10.3892/mmr.2019.10809

miR‑218 functions as a tumor suppressor gene in cervical cancer

Authors:
- Zhen Liu
- Lin Mao
- Linlin Wang
- Hong Zhang
- Xiaoxia Hu
View Affiliations

Affiliations: Department of Gynecology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, P.R. China, Department of Gynecology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: November 11, 2019 https://doi.org/10.3892/mmr.2019.10809
Pages: 209-219
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous microRNA (miR) microarray analysis revealed that miR‑218 is downregulated in cervical cancer tissues. The present study aimed to further evaluate the expression of miR‑218 in cervical cancer specimens, determine the association between its expression with disease progression, and investigate the roles of miR‑218 in cervical cancer cells. Tissue specimens were obtained from 80 patients with cervical squamous cell carcinoma, 30 patients with high‑grade cervical intraepithelial neoplasia [(CIN) II/III] and 15 patients with low‑grade CIN (CINI); in addition, 60 plasma samples were obtained from patients with cervical cancer, and 15 normal cervical tissue specimens and 30 plasma samples were obtained from healthy women. These samples were used for analysis of miR‑218 expression via reverse transcription‑quantitative PCR. In addition, tumor cells were transfected with miR‑218 mimics, human papillomavirus (HPV)16 E6/E7 small interfering RNA, or their respective negative controls to determine the viability, colony formation, migration and invasion of cells using MTT, colony formation, wound healing and Transwell assays, respectively. Target genes of miR‑218 were bioinformatically predicted and analyzed using Gene Ontology (GO) terms. The results revealed that miR‑218 was downregulated in the tumor tissues and plasma of patients with cervical cancer, with expression associated with the advanced clinicopathological characteristics of patients, including HPV positivity, tumor size, blood vessel invasion and lymph node metastasis. Furthermore, miR‑218 overexpression reduced tumor cell viability and xenograft growth, and suppressed tumor cell migration and invasion. HPV was detected in 75% of the 80 patients with cervical cancer, and HPV positivity was inversely associated with miR‑218 expression. In addition, bioinformatics analysis predicted that roundabout guidance receptor 1 (ROBO1) was a target gene of miR‑218; miR‑218 overexpression significantly reduced ROBO1 levels. Furthermore, GO analysis revealed that ROBO1 was involved in regulating cell proliferation, adhesion and migration, and the cell cycle. In conclusion, the findings of the present study suggested that miR‑218 may possess antitumor activities in cervical cancer.

View Figures

View References

1	Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A and Colombo N; ESMO Guidelines Committee, : Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 29 (Supplement_4):v2622018. View Article : Google Scholar
2	Tran NP, Hung CF, Roden R and Wu TC: Control of HPV infection and related cancer through vaccination. Recent Results Cancer Res. 193:149–171. 2014. View Article : Google Scholar : PubMed/NCBI
3	Gadducci A, Barsotti C, Cosio S, Domenici L and Riccardo Genazzani A: Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: A review of the literature. Gynecol Endocrinol. 27:597–604. 2011. View Article : Google Scholar : PubMed/NCBI
4	Bosch FX and de Sanjose S: The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers. 23:213–227. 2007. View Article : Google Scholar : PubMed/NCBI
5	Jones WB, Mercer GO, Lewis JL Jr, Rubin SC and Hoskins WJ: Early invasive carcinoma of the cervix. Gynecol Oncol. 51:26–32. 1993. View Article : Google Scholar : PubMed/NCBI
6	Waggoner SE: Cervical cancer. Lancet. 361:2217–2225. 2003. View Article : Google Scholar : PubMed/NCBI
7	Lin Y, Zhou J, Dai L, Cheng Y and Wang J: Vaginectomy and vaginoplasty for isolated vaginal recurrence 8 years after cervical cancer radical hysterectomy: A case report and literature review. J ObstetGynaecol Res. 43:1493–1497. 2017.
8	Ramirez PT and Salvo G: Gynecological Tumors. Cervical cancer (Internet) MSD Manual; New Jersey, USA: 2018
9	Shukla GC, Singh J and Barik S: MicroRNAs: Processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
10	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
11	Chiantore MV, Mangino G, Iuliano M, Zangrillo MS, De Lillis I, Vaccari G, Accardi R, Tommasino M, Fiorucci G and Romeo G: IFN-β antiproliferative effect and miRNA regulation in human papilloma virus E6- and E7-transformed keratinocytes. Cytokine. 89:235–238. 2017. View Article : Google Scholar : PubMed/NCBI
12	Jimenez-Wences H, Martinez-Carrillo DN, Peralta-Zaragoza O, Campos-Viguri GE, Hernández-Sotelo D, Jiménez-López MA, Muñoz-Camacho JG, Garzón-Barrientos VH, Illades-Aguiar B and Fernández-Tilapa G: Methylation and expression of miRNAs in precancerous lesions and cervical cancer with HPV16 infection. Oncol Rep. 35:2297–2305. 2016. View Article : Google Scholar : PubMed/NCBI
13	Chhabra R: let-7i-5p, miR-181a-2-3p and EGF/PI3K/SOX2 axis coordinate to maintain cancer stem cell population in cervical cancer. Sci Rep. 8:78402018. View Article : Google Scholar : PubMed/NCBI
14	Gao C, Zhou C, Zhuang J, Liu L, Liu C, Li H, Liu G, Wei J and Sun C: MicroRNA expression in cervical cancer: Novel diagnostic and prognostic biomarkers. J Cell Biochem. 119:7080–7090. 2018. View Article : Google Scholar : PubMed/NCBI
15	Kawai S, Fujii T, Kukimoto I, Yamada H, Yamamoto N, Kuroda M, Otani S, Ichikawa R, Nishio E, Torii Y and Iwata A: Identification of miRNAs in cervical mucus as a novel diagnostic marker for cervical neoplasia. Sci Rep. 8:70702018. View Article : Google Scholar : PubMed/NCBI
16	Chen Z, Han Y, Song C, Wei H, Chen Y, Huang K, Li S, Ma D, Wang S, Wang J and Lu Q: Systematic review and meta-analysis of the prognostic significance of microRNAs in cervical cancer. Oncotarget. 9:17141–17148. 2017.PubMed/NCBI
17	Peta E, Sinigaglia A, Masi G, Di Camillo B, Grassi A, Trevisan M, Messa L, Loregian A, Manfrin E, Brunelli M, et al: HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys. Oncogene. 37:1654–1668. 2018. View Article : Google Scholar : PubMed/NCBI
18	Honegger A, Schilling D, Sultmann H, Hoppe-Seyler K and Hoppe-Seyler F: Identification of E6/E7-dependent MicroRNAs in HPV-positive cancer cells. Methods Mol Biol. 1699:119–134. 2018. View Article : Google Scholar : PubMed/NCBI
19	Srivastava SK, Ahmad A, Zubair H, Miree O, Singh S, Rocconi RP, Scalici J and Singh AP: MicroRNAs in gynecological cancers: Small molecules with big implications. Cancer Lett. 407:123–138. 2017. View Article : Google Scholar : PubMed/NCBI
20	Zeng K, Zheng W, Mo X, Liu F, Li M, Liu Z, Zhang W and Hu X: Dysregulated microRNAs involved in the progression of cervical neoplasm. Arch Gynecol Obstet. 292:905–913. 2015. View Article : Google Scholar : PubMed/NCBI
21	Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, et al: MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 71:2381–2391. 2011. View Article : Google Scholar : PubMed/NCBI
22	Zhang X, Dong J, He Y, Zhao M, Liu Z, Wang N, Jiang M, Zhang Z, Liu G, Liu H, et al: miR-218 inhibited tumor angiogenesis by targeting ROBO1 in gastric cancer. Gene. 615:42–49. 2017. View Article : Google Scholar : PubMed/NCBI
23	Gu JJ, Gao GZ and Zhang SM: MiR-218 inhibits the tumorgenesis and proliferation of glioma cells by targetingRobo1. Cancer Biomark. 16:309–317. 2016. View Article : Google Scholar : PubMed/NCBI
24	Yang M, Liu R, Li X, Liao J, Pu Y, Pan E, Wang Y and Yin L: Epigenetic repression of miR-218 promotes esophageal carcinogenesis by targetingROBO1. Int J Mol Sci. 16:27781–27795. 2015. View Article : Google Scholar : PubMed/NCBI
25	Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C, Bothou A and Galazios G: Cervical cancer: Screening, diagnosis and staging. J BUON. 21:320–325. 2016.PubMed/NCBI
26	Feldman AT and Wolfe D: Tissue processing and hematoxylin and eosin staining. Methods Mol Biol. 1180:31–43. 2014. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Aiso T, Sekine N, Takagi Y and Ohnishi H: Study on the sample preservation temperature and period in circulating MicroRNAQuantification using spike-in control. Rinsho Byori. 63:688–693. 2015.(In Japanese). PubMed/NCBI
29	Barreto CL, Martins DB, de Lima Filho JL and Magalhães V: Detection of human papillomavirus in biopsies of patients with cervical cancer, and its association with prognosis. Arch Gynecol Obstet. 288:643–648. 2013. View Article : Google Scholar : PubMed/NCBI
30	Di Martino MT, Campani V, Misso G, Gallo Cantafio ME, Gullà A, Foresta U, Guzzi PH, Castellano M, Grimaldi A, Gigantino V, et al: In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS One. 9:e900052014. View Article : Google Scholar : PubMed/NCBI
31	Li Y, Liu J, Yuan C, Cui B, Zou X and Qiao Y: High-risk human papillomavirus reduces the expression of microRNA-218 in women with cervical intraepithelial neoplasia. J Int Med Res. 38:1730–1736. 2010. View Article : Google Scholar : PubMed/NCBI
32	Jiang Z, Song Q, Zeng R, Li J, Li J, Lin X, Chen X, Zhang J and Zheng Y: MicroRNA-218 inhibits EMT, migration and invasion by targeting SFMBT1 and DCUN1D1 in cervical cancer. Oncotarget. 7:45622–45636. 2016.PubMed/NCBI
33	Huang YH, Liang KH, Chien RN, Hu TH, Lin KH, Hsu CW, Lin CL, Pan TL, Ke PY and Yeh CT: A circulating MicroRNA signature capable of assessing the risk of hepatocellularcarcinoma in cirrhotic patients. Sci Rep. 7:5232017. View Article : Google Scholar : PubMed/NCBI
34	Zhang K, Wang YW, Wang YY, Song Y, Zhu J, Si PC and Ma R: Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling. Gene. 619:10–20. 2017. View Article : Google Scholar : PubMed/NCBI
35	Decmann A, Perge P, Nagy Z, Butz H, Patócs A and Igaz P: Circulating microRNAs in the diagnostics of endocrine neoplasms. Orv Hetil. 158:483–490. 2017.(In Hungarian). View Article : Google Scholar : PubMed/NCBI
36	Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, et al: Detection of elevated levels of tumour-associated microRNAs in serum of patientswith diffuse large B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
37	Sun Y, Wang M, Lin G, Sun S, Li X, Qi J and Li J: Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One. 7:e470032012. View Article : Google Scholar : PubMed/NCBI
38	Kessler TA: Cervical cancer: Prevention and early detection. SeminOncol Nurs. 33:172–183. 2017.
39	Lu Z, Chen H, Zheng XM and Chen ML: Expression and clinical significance of high risk human papillomavirus and invasive gene in cervical carcinoma. Asian Pac J Trop Med. 10:195–200. 2017. View Article : Google Scholar : PubMed/NCBI
40	Ben W, Yang Y, Yuan J, Sun J, Huang M, Zhang D and Zheng J: Human papillomavirus 16 E6 modulates the expression of host microRNAs in cervical cancer. Taiwan J Obstet Gynecol. 54:364–370. 2015. View Article : Google Scholar : PubMed/NCBI
41	Nambaru L, Meenakumari B, Swaminathan R and Rajkumar T: Prognostic significance of HPV physical status and integration sites in cervical cancer. Asian Pac J Cancer Prev. 10:355–360. 2009.PubMed/NCBI
42	Song L, Liu S, Zeng S, Zhang L and Li X: miR-375 modulates radiosensitivity of HR-HPV-positive cervical cancer cells by targeting UBE3A through the p53 pathway. Med Sci Monit. 21:2210–2217. 2015. View Article : Google Scholar : PubMed/NCBI
43	Liu X: Up-regulation of miR-20a by HPV16 E6 exerts growth-promoting effects by targeting PDCD6 in cervical carcinoma cells. Biomed Pharmacother. 102:996–1002. 2018. View Article : Google Scholar : PubMed/NCBI
44	Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP and Khan SA: Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene. 27:2575–2582. 2008. View Article : Google Scholar : PubMed/NCBI
45	Sun X, Song S, Liang X, Xie Y, Zhao C, Zhang Y, Shu H and Gong G: ROBO1 polymorphisms, callosal connectivity, and reading skills. Hum Brain Mapp. 38:2616–2626. 2017. View Article : Google Scholar : PubMed/NCBI
46	Wang J, Zhou Y, Fei X, Chen X, Chen R, Zhu Z and Chen Y: Integrative bioinformatics analysis identifies ROBO1 as a potential therapeutic target modified by miR-218 in hepatocellular carcinoma. Oncotarget. 8:61327–61337. 2017.PubMed/NCBI
47	Gu JJ, Gao GZ and Zhang SM: miR-218 inhibits the migration and invasion of glioma U87 cells through the Slit2-Robo1 pathway. Oncol Lett. 9:1561–1566. 2015. View Article : Google Scholar : PubMed/NCBI